Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 11« First...34567...10...Last »

Vitamin C May Encourage Blood Cancer Stem Cells to Die

Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone Health, and published online August 17, 2017, in the journal Cell.

Read More »

Novo Nordisk’s semaglutide beats out Trulicity

Positive results were announced from Novo Nordisk’s SUSTAIN 7 Phase III trial comparing once-weekly semaglutide against Lilly’s Trulicity for type 2 diabetes.

Read More »

House Democrats launch MS drug pricing probe

House Committee on Oversight and Government Reform Democrats are launching an investigation into why prices for MS treatments have nearly quadrupled since 2004.

Read More »

Innovation and robotics will speed up tumor analysis

Genome BC is investing in a cancer research project that aims to speed up genetic tests of tumors through the development of a robotics system.

Read More »

Mylan, U.S. finalize EpiPen settlement

Mylan NV finalized a $465 million settlement with the U.S. Justice Department, resolving claims it overcharged the government for its EpiPen emergency allergy treatment.

Read More »

Arcus Biosciences, Wuxi Biologics Hammer Out R&D Cancer Pact Worth $816 Million+

One year after emerging from stealth mode, immuno-oncology startup Arcus Biosciences struck an exclusive licensing deal with Shanghai, China-based Wuxi Biologics for its anti-PD-1 antibody GLS-010.

Read More »

Johnson & Johnson CEO Backpedals and Quits Right Before Trump Disbands Council

One day after committing to remain on the President’s Manufacturing Council, Johnson & Johnson Chief Executive Officer Alex Gorsky reversed course and resigned from the council, shortly before the council as a whole was disbanded by President Donald Trump.

Read More »

Repatha Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

Amgen announced that the New England Journal of Medicine published results from the Repatha (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).

Read More »

Trump to make August cost-sharing payments to health insurers

The Trump administration will make cost-sharing payments to insurance companies under Obamacare for August 2017, a White House spokesman said, but the announcement did little to quell long-term concerns about the insurance market.

Read More »

FDA Accepts Adcetris Supplemental BLA for CTLC

The FDA accepted for filing Seattle Genetics’ supplemental Biologics License Application for Adcetris in patients with cutaneous T-cell lymphoma.

Read More »

How Eli Lilly Allegedly Used a Fake Rule and Fake News to Protect Bad Patents

Although the dust may have settled from a Canadian lawsuit Eli Lilly lost over patents for two of its drugs, Zyprexa and Strattera, questions remain over the manner in which the Indianapolis-based company fought in court.

Read More »

Bristol-Myers Kidney Cancer Drug Flunks Study

Bristol-Myers Squibb released mixed top-line results from its Phase III CheckMate-214 clinical trial of Opdivo in combination with Yervoy for advanced or metastatic RCC.

Read More »

W2O Group’s Sentient Adds Dominic Viola and Michael Spitz To Leadership Team

W2O Sentient announced the appointment of respected industry leaders Dominic Viola as Managing Director, Client Services, and Michael Spitz as Practice Leader, Strategy.

Read More »

End of U.S. payments to health insurers would cause premiums to rise: CBO

Health insurance premiums for many customers on the Obamacare individual insurance markets would be 20 percent higher in 2018 if U.S. President Donald Trump follows through on a threat to stop billions of dollars of payments to health insurers, a nonpartisan congressional office said.

Read More »

Flimsy evidence behind many FDA approvals

Many drugs granted accelerated approval and most high-risk medical devices approved by FDA lack clear evidence of safety and effectiveness, per JAMA reports.

Read More »

Centene to sell Obamacare plans in Nevada during 2018

Centene Corp., one of the largest players in the Obamacare individual insurance market, said it would offer Obamacare plans in Nevada in 2018.

Read More »

Lack of sleep tied to higher risk of diabetes in kids

Children who do not get enough sleep may be more likely to develop diabetes than kids who typically get enough shuteye, a UK study suggests.

Read More »

South Carolina sues OxyContin maker Purdue

South Carolina sued Purdue Pharma, accusing the OxyContin maker of deceptive marketing practices that have contributed to a national opioid addiction epidemic.

Read More »

Discovery Worldwide Names Stephanie Franke as VP, Creative Director

Discovery Worldwide announced the appointment of Stephanie Franke as VP, Creative Director. Franke reports directly to TJ Cimfel, Group VP Creative Director.

Read More »

Takeda Forges Alliance with Stanford University

Takeda Pharmaceutical announced a collaboration to help transform novel Stanford University research into next-generation treatments for diseases.

Read More »

Page 5 of 11« First...34567...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom